Status:
UNKNOWN
Pharmacologic Ascorbic Acid as an Activator of Lymphocyte Signaling for COVID-19 Treatment
Lead Sponsor:
Thomas Jefferson University
Conditions:
COVID-19
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
There are currently no approved therapies for patients with coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Infusion of ascorbic acid (vitamin C)...
Detailed Description
Ascorbic acid \[AA\] (vitamin C) is an essential nutrient that, in addition to aiding tissue repair, also functions as an enzyme co-factor, an antioxidant, and a key component in lymphocyte developmen...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Male or non-pregnant female \> 18 years of age at the time of consent
- ConfirmedSARS-CoV-2 infection
- Disease severity necessitating hospitalization
- Currently taking supplemental oxygen
- No anticipated need (within 24 hours) for mechanical ventilation, defined as:
- Positive clinical response to oxygen supplementation with improvement in hypoxia or
- Hypoxia improvement with bronchospasm therapy if bronchospasm present
- Exclusion Criteria
- eGFR \< 50
- Known Glucose-6-phosphate dehydrogenase (G6PD) deficiency
- Anticipated need for mechanical ventilation within 24 hours
- Pregnant or breastfeeding
- Requires home oxygen for any reason
Exclusion
Key Trial Info
Start Date :
May 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2021
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT04363216
Start Date
May 1 2020
End Date
May 1 2021
Last Update
May 5 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.